Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

REST - Replacing Steroids in the Transplant Ineligble

NCT04939844

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Zealand University Hospital Roskilde, Denmark
  • Oslo University Hospital Oslo, Norway
  • Helse Stavanger HF Stavanger, Norway
  • St. Olav University Hospital Trondheim, Norway
View Trial Details
Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinical Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790

Conditions
Acute Myeloid Leukemia (AML), Blood Protein Disorders, Bone Marrow Diseases, +33 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Oncology Institute of Hope and Innovation Pasadena, California, United States
  • Rocky Mountain Regional VA Medical Center Aurora, Colorado, United States
  • Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute) Denver, Colorado, United States
View all 46 locations
View Trial Details
Completed

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSD Medical Center - Encinitas Encinitas, California, United States
  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital) La Jolla, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 37 locations
View Trial Details
Completed

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03544281

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Goodyear, Arizona, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Indianapolis, Indiana, United States
View all 26 locations
View Trial Details
Completed

Ixazomib Rollover Study

NCT02924272

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +18 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Appalachian Regional Healthcare Hazard, Kentucky, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 26 locations
View Trial Details

Related conditions